Search
dornase alfa; nebulized recombinant human DNase (Pulmozyme, rhDNAse, nrhDNAse)
Tradename: Pulmozyme.
Indications:
- cystic fibrosis (CF)
a) to reduce frequency of respiratory tract infections that require antibiotics
b) to improve pulmonary function
c) early treatment of benefit (protective effect) [3]
d) role in increased longevity of patients with CF [5]
Dosage:
- Cystic fibrosis: 2.5 mg nebulized QD [4] (or QOD [3])
Storage: 2-8 degrees C, protect from light
Adverse effects:
1) common (> 10%)
- alteration of voice
- hoarseness
- rash
- chest pain
- pharyngitis
2) less common (1-10%)
- laryngitis, cough, dyspnea, hemoptysis, rhinitis, wheezing, conjunctivitis
Mechanism of action:
- Aerosolized recombinant human DNAse 1.
General
deoxyribonuclease [DNase]-1 (DNASE1, DNL1, DRNI)
recombinant protein; chimer
mucolytic agent
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Journal Watch 21(24):198, 2001
Suri R et al
Comparison of hypertonic saline and alternate-day or
daily recombinant human deoxyribonuclease in children
with cystic fibrosis: a randomised trial.
Lancet 358:1316, 2001
PMID: 11684212
- Journal Watch 22(3):20, 2002
Quan JM et al,
A two-year randomized, placebo-controlled trial of
dornase alfa in young patients with cystic fibrosis
with mild lung function abnormalities.
J Pediatr 139:813, 2001
PMID: 11743506
- George PM et al.
Improved survival at low lung function in cystic fibrosis:
Cohort study from 1990 to 2007.
BMJ 2011 Feb 28; 342:d1008
PMID: 21357627
- Pulmozyme; note=Clinical information on Pulmozyme
http://www.pulmozyme.com/patient/0_0_index.jsp